Hims and Hers to offer weight-loss treatments in UK

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Hims and Hers to start weight-loss jab subscription in UK

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

Novo Nordisk Stumbles as Obesity Drug Race Heats Up

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.
Moneyweb

Novo Nordisk is trading as if obesity drug craze never happened

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

A Stumble for a Former Star: Novo Nordisk's Challenging Year

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...
newscase

Novo Nordisk Shares Plunge as Weight-Loss Drug Dominance Fades

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

8 FDA-approved weight loss drugs: What are they & what are their side effects?

FDA-approved weight loss medications include injections (Wegovy®, Zepbound®, etc.) and pills, like Qsymia® and Xenical®. Most ...

Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...